Maxim keeps a Buy rating on Palisade Bio with a $22.50 saying the company announced additional positive pre-clinical ex-vivo data for PALI-2108 finding it has anti-TNF activity. PALI-2108 is being developed for treating ulcerative colitis and this data further supports development and potential in treating of UC, the analyst tells investors in a research note. The firm believes that while the development and marketing in UC is challenging, there is a market opportunity for an oral PDE4 and Palisade’s preclinical data is promising. Maxim keeps a Buy rating on the shares with a $22.50 price target.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PALI:
- Palisade Bio’s Lead Product Candidate, PALI-2108 Demonstrates Potent Anti-Inflammatory Effects in Ex-Vivo Study of Whole Blood Samples Challenged with Pro-Inflammatory Lipopolysaccharide (LPS)
- Palisade Bio Enters into Strategic Collaboration with Strand Life Sciences to Advance Precision Medicine Approach
- Palisade Bio enters strategic collaboration with Strand Life Sciences
- Palisade Bio Successfully Demonstrates Bioactivation of PALI-2108 In Ex-Vivo Study of Normal Healthy and Ulcerative Colitis Patients’ Stool
- Palisade Bio demonstrates bioactivation of PALI-2108